191 related articles for article (PubMed ID: 10418898)
1. The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1.
Moore A; McCarthy L; Mills KH
Vaccine; 1999 Jun; 17(20-21):2517-27. PubMed ID: 10418898
[TBL] [Abstract][Full Text] [Related]
2. Differential immune responses to HIV-1 envelope protein induced by liposomal adjuvant formulations containing monophosphoryl lipid A with or without QS21.
Beck Z; Matyas GR; Jalah R; Rao M; Polonis VR; Alving CR
Vaccine; 2015 Oct; 33(42):5578-5587. PubMed ID: 26372857
[TBL] [Abstract][Full Text] [Related]
3. Identification of QS-21 as an Inflammasome-activating Molecular Component of Saponin Adjuvants.
Marty-Roix R; Vladimer GI; Pouliot K; Weng D; Buglione-Corbett R; West K; MacMicking JD; Chee JD; Wang S; Lu S; Lien E
J Biol Chem; 2016 Jan; 291(3):1123-36. PubMed ID: 26555265
[TBL] [Abstract][Full Text] [Related]
4. An engineered mutant of HIV-1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4-binding site.
Ahmed FK; Clark BE; Burton DR; Pantophlet R
Vaccine; 2012 Jan; 30(5):922-30. PubMed ID: 22142583
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of monophosphoryl lipid A augmentation of host responses to recombinant HagB from Porphyromonas gingivalis.
Yang QB; Martin M; Michalek SM; Katz J
Infect Immun; 2002 Jul; 70(7):3557-65. PubMed ID: 12065496
[TBL] [Abstract][Full Text] [Related]
6. Vaccine adjuvants CpG (oligodeoxynucleotides ODNs), MPL (3-O-deacylated monophosphoryl lipid A) and naloxone-enhanced Th1 immune response to the Plasmodium vivax recombinant thrombospondin-related adhesive protein (TRAP) in mice.
Nazeri S; Zakeri S; Mehrizi AA; Djadid ND; Snounou G; Andolina C; Nosten F
Med Microbiol Immunol; 2018 Nov; 207(5-6):271-286. PubMed ID: 29948091
[TBL] [Abstract][Full Text] [Related]
7. Adsorption to aluminum hydroxide promotes the activity of IL-12 as an adjuvant for antibody as well as type 1 cytokine responses to HIV-1 gp120.
Jankovic D; Caspar P; Zweig M; Garcia-Moll M; Showalter SD; Vogel FR; Sher A
J Immunol; 1997 Sep; 159(5):2409-17. PubMed ID: 9278332
[TBL] [Abstract][Full Text] [Related]
8. Enhanced Immunogenicity and Protective Efficacy of a
Ramakrishnan A; Schumack NM; Gariepy CL; Eggleston H; Nunez G; Espinoza N; Nieto M; Castillo R; Rojas J; McCoy AJ; Beck Z; Matyas GR; Alving CR; Guerry P; Poly F; Laird RM
mSphere; 2019 May; 4(3):. PubMed ID: 31043512
[No Abstract] [Full Text] [Related]
9. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.
Vandepapelière P; Horsmans Y; Moris P; Van Mechelen M; Janssens M; Koutsoukos M; Van Belle P; Clement F; Hanon E; Wettendorff M; Garçon N; Leroux-Roels G
Vaccine; 2008 Mar; 26(10):1375-86. PubMed ID: 18272264
[TBL] [Abstract][Full Text] [Related]
10. Increased immunogenicity of HIV envelope subunit complexed with alpha2-macroglobulin when combined with monophosphoryl lipid A and GM-CSF.
Liao HX; Cianciolo GJ; Staats HF; Scearce RM; Lapple DM; Stauffer SH; Thomasch JR; Pizzo SV; Montefiori DC; Hagen M; Eldridge J; Haynes BF
Vaccine; 2002 May; 20(17-18):2396-403. PubMed ID: 12009296
[TBL] [Abstract][Full Text] [Related]
11. Potentiating effects of MPL on DSPC bearing cationic liposomes promote recombinant GP63 vaccine efficacy: high immunogenicity and protection.
Mazumder S; Maji M; Ali N
PLoS Negl Trop Dis; 2011 Dec; 5(12):e1429. PubMed ID: 22206029
[TBL] [Abstract][Full Text] [Related]
12. Monophosphoryl lipid A enhances both humoral and cell-mediated immune responses to DNA vaccination against human immunodeficiency virus type 1.
Sasaki S; Tsuji T; Hamajima K; Fukushima J; Ishii N; Kaneko T; Xin KQ; Mohri H; Aoki I; Okubo T; Nishioka K; Okuda K
Infect Immun; 1997 Sep; 65(9):3520-8. PubMed ID: 9284115
[TBL] [Abstract][Full Text] [Related]
13. Generation of Th1 immune responses to inactivated, gp120-depleted HIV-1 in mice with a dominant Th2 biased immune profile via immunostimulatory [correction of imunostimulatory] oligonucleotides--relevance to AIDS vaccines in developing countries.
Ayash-Rashkovsky M; Weisman Z; Diveley J; Moss RB; Bentwich Z; Borkow G
Vaccine; 2002 Jun; 20(21-22):2684-92. PubMed ID: 12034094
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis C virus-like particles combined with novel adjuvant systems enhance virus-specific immune responses.
Qiao M; Murata K; Davis AR; Jeong SH; Liang TJ
Hepatology; 2003 Jan; 37(1):52-9. PubMed ID: 12500188
[TBL] [Abstract][Full Text] [Related]
15. STAT4 is required for the generation of Th1 and Th2, but not Th17 immune responses during monophosphoryl lipid A adjuvant activity.
Varikuti S; Oghumu S; Natarajan G; Kimble J; Sperling RH; Moretti E; Kaplan MH; Satoskar AR
Int Immunol; 2016 Nov; 28(11):565-570. PubMed ID: 27578456
[TBL] [Abstract][Full Text] [Related]
16. Pertussis toxin potentiates Th1 and Th2 responses to co-injected antigen: adjuvant action is associated with enhanced regulatory cytokine production and expression of the co-stimulatory molecules B7-1, B7-2 and CD28.
Ryan M; McCarthy L; Rappuoli R; Mahon BP; Mills KH
Int Immunol; 1998 May; 10(5):651-62. PubMed ID: 9645613
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and HIV-1 virus neutralization of MN recombinant glycoprotein 120/HIV-1 QS21 vaccine in baboons .
Powell MF; Cleland JL; Eastman DJ; Lim A; Murthy K; Newman MJ; Nunberg JH; Weissburg RP; Vennari JC; Wrin T
AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S105-8. PubMed ID: 7865282
[TBL] [Abstract][Full Text] [Related]
18. A Th1-inducing adjuvant, MPL, enhances antibody profiles in experimental animals suggesting it has the potential to improve the efficacy of allergy vaccines.
Wheeler AW; Marshall JS; Ulrich JT
Int Arch Allergy Immunol; 2001 Oct; 126(2):135-9. PubMed ID: 11729351
[TBL] [Abstract][Full Text] [Related]
19. Role of CD80 and CD86 in host immune responses to the recombinant hemagglutinin domain of Porphyromonas gingivalis gingipain and in the adjuvanticity of cholera toxin B and monophosphoryl lipid A.
Zhang P; Lewis JP; Michalek SM; Katz J
Vaccine; 2007 Aug; 25(33):6201-10. PubMed ID: 17629367
[TBL] [Abstract][Full Text] [Related]
20. A phase I trial in HIV negative healthy volunteers evaluating the effect of potent adjuvants on immunogenicity of a recombinant gp120W61D derived from dual tropic R5X4 HIV-1ACH320.
McCormack S; Tilzey A; Carmichael A; Gotch F; Kepple J; Newberry A; Jones G; Lister S; Beddows S; Cheingsong R; Rees A; Babiker A; Banatvala J; Bruck C; Darbyshire J; Tyrrell D; Van Hoecke C; Weber J
Vaccine; 2000 Jan; 18(13):1166-77. PubMed ID: 10649617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
